London (ots/PRNewswire) - - Eisai Plans to Submit Marketing Authorization Applications for. Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from a recently completed Phase III study with E7389 (generic name: eribulin ...
Tokyo, Japan (ots/PRNewswire) - E2007 (perampanel) is a first-in-class, orally administered, highly selective non-competitive AMPA-type glutamate receptor antagonist, in development by Eisai (TSE:4523) for several indications, including Parkinson's disease, neuropathic pain, epilepsy, multiple sclerosis and ...
London (ots/PRNewswire) - - For the Attention of Business and Healthcare Editors Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya). ...
Tokyo (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that the company has signed on May 14, 2007 (the U.S. Eastern Time) the exclusive agreement with Solstice Neurosciences, Inc. (Headquarters: Pennsylvania, U.S., President & CEO: Shawn Patrick O'Brien) for NeuroBloc(R) , an injectable form of botulinum toxin ...
Tokyo, Japan, Woodcliff Lake, New Jersey and Exton, Pennsylvania (ots/PRNewswire) - - Eisai's Dramatic Leap Towards Biologic Therapeutics Evidenced by the Acquisition Eisai Co., Ltd. (Tokyo, "Eisai", President and CEO: Haruo Naito), Eisai Corporation of North America (Woodcliff Lake, NJ, "ECA", President: Hajime Shimizu) and Morphotek(R) Inc. (Exton, PA, "Morphotek", CEO: Nicholas Nicolaides) today announce that ECA has signed a definitive agreement to acquire ...
Tokyo, Japan (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from the latest donepezil (Product name: ARICEPT(R)) study (Study 319) on the treatment of people with vascular dementia (VaD). Preliminary efficacy results show that those who received donepezil improved on measures of cognition, ...